BARD1 anticorps (N-Term)

N° du produit ABIN654621

Détail du produit anti-BARD1 anticorps

Antigène: BARD1 (BRCA1 Associated RING Domain 1 (BARD1))

Épitope: AA 101-131, N-Term

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp BARD1 est non-conjugé

Application: Western Blotting (WB)

Purification: This antibody is purified through a protein A column, followed by peptide affinity purification.

Immunogène: This BARD1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 101-131 amino acids from the N-terminal region of human BARD1.

Clone: RB19063

Isotype: Ig Fraction

Information d'application

Indications d'application: WB: 1:1000

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C,-20 °C

Stockage commentaire: Maintain refrigerated at 2-8 °C for up to 6 months. For long term storage store at -20 °C in small aliquots to prevent freeze-thaw cycles.

Date de péremption: 6 months

Détails sur BARD1

Antigène: BARD1 (BRCA1 Associated RING Domain 1 (BARD1))

Autre désignation: BARD1 (BARD1 Produits)

Synonymes: anticorps BARD1, anticorps LOC100147913, anticorps ENSMUSG00000060893, anticorps ENSMUSG00000073653, anticorps BRCA1 associated RING domain 1, anticorps BARD1, anticorps bard1, anticorps Bard1

Sujet: BARD1 is a protein which interacts with the N-terminal region of BRCA1. In addition to its ability to bind BRCA1 in vivo and in vitro, it shares homology with the 2 most conserved regions of BRCA1: the N-terminal RING motif and the C-terminal BRCT domain. The RING motif is a cysteine-rich sequence found in a variety of proteins that regulate cell growth, including the products of tumor suppressor genes and dominant protooncogenes. This protein also contains 3 tandem ankyrin repeats. The BARD1/BRCA1 interaction is disrupted by tumorigenic amino acid substitutions in BRCA1, implying that the formation of a stable complex between these proteins may be an essential aspect of BRCA1 tumor suppression. This protein may be the target of oncogenic mutations in breast or ovarian cancer.

Poids moléculaire: 86648

ID gène: 580

NCBI Accession: NP_000456

UniProt: Q99728

Pathways: Réparation de l'ADN